研究进展在瘤中葡萄糖代谢重编程和乳糖化之间的相互作用
Yi Yang1,2, Yi Wu2,3, Hui Chen1,2
1Department of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Nantong, China.
Frontiers in immunology
|August 4, 2025
概括
葡萄糖代谢重编程增强了葡萄糖分解,增加了乳酸. 这种乳酸积累导致乳化,一种表观遗传修饰,影响基因表达,抑制抗瘤免疫力,促进癌症的进展.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 葡萄糖代谢重编程改变细胞代谢以快速产生ATP,即使在富含氧气的条件下.
- 这一过程导致乳酸的积累,影响瘤和瘤微环境 (TME) 内的免疫细胞.
- 乳化是一种翻译后的修饰,由乳酸的积累引起,影响蛋白质功能和基因表达.
研究的目的:
- 审查乳酸和葡萄糖代谢重编程的机制.
- 探索它们对TME内的免疫细胞的影响.
- 阐明它们在瘤进展,免疫力和炎症中的相互关系.
主要方法:
- 审查关于葡萄糖代谢,乳糖和癌症免疫学的现有文献.
- 对链接葡萄糖代谢,乳酸生产和表观遗传修饰的分子途径的分析.
- 检查乳化对免疫细胞功能和瘤微环境的影响.
主要成果:
- 葡萄糖重编程通过转录因子 (HIF-1α,c-Myc) 激活关键酶 (HK2,PKM2,LDHA),促进糖解和乳酸.
- 乳酸作为乳化基质,由CBP/p300等酶介导,改变蛋白质功能和基因表达.
- 乳化抑制抗瘤免疫力,通过调节瘤性途径,促进M2巨细胞的两极分化,并导致T细胞功能障碍.
结论:
- 葡萄糖代谢重编程和乳糖化相互关联,通过影响基因表达,蛋白质功能和TME来驱动瘤发生.
- 这些过程有助于免疫逃避和癌症的进展.
- 了解这些机制为癌症治疗提供了潜在的治疗点.
相关概念视频
Adaptive Mechanisms in Cancer Cells
5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Glucose Homeostasis: Regulation of Blood Glucose
2.5K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
2.5K
Hormones Regulating Blood Glucose
4.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
4.0K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K
Glucagon-like Receptor Agonists
419
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
419
Hypoglycemia and Glucagon
337
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
337


